Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 5Stomach Neoplasms 4Advanced Gastric Cancer 3Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Diseases 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lung Diseases 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Liver Neoplasms 1Hepatic Metastasis of Colorectal Cancer 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Colorectal Cancer Recurrent 1Biliary Tract Neoplasms 1Advanced Triple Negative Breast Cancer 1Advanced Solid Tumors 1

Interventions

Ifosfamide 5Temozolomide 4surufatinib 2irinotecan sucrosofate 2Vincristine 2Radiotherapy 2Nivolumab 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2vactosertib 1temsirolimus 1talazoparib 1silmitasertib 1selinexor 1regorafenib 1pepinemab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lenvatinib 1etoposide phosphate 1endostar protein 1dostarlimab 1dinutuximab 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Osteosarcoma × apatinib × Clear all
NCT07479732 2026-03-18

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

Peking University People's Hospital

Phase 1/2 Recruiting
56 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡